272 related articles for article (PubMed ID: 28634000)
1. Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study.
O'Dell MW; Brashear A; Jech R; Lejeune T; Marque P; Bensmail D; Ayyoub Z; Simpson DM; Volteau M; Vilain C; Picaut P; Gracies JM
PM R; 2018 Jan; 10(1):1-10. PubMed ID: 28634000
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Hemiparesis in Adults With Upper Limb Spasticity Previously Treated With Botulinum Toxin: Subanalysis From a Phase 3 Randomized Controlled Trial.
Marciniak C; McAllister P; Walker H; Brashear A; Edgley S; Deltombe T; Khatkova S; Banach M; Gul F; Vilain C; Picaut P; Grandoulier AS; Gracies JM;
PM R; 2017 Dec; 9(12):1181-1190. PubMed ID: 28625615
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.
Gracies JM; Brashear A; Jech R; McAllister P; Banach M; Valkovic P; Walker H; Marciniak C; Deltombe T; Skoromets A; Khatkova S; Edgley S; Gul F; Catus F; De Fer BB; Vilain C; Picaut P;
Lancet Neurol; 2015 Oct; 14(10):992-1001. PubMed ID: 26318836
[TBL] [Abstract][Full Text] [Related]
4. Effects of repeated abobotulinumtoxinA injections in upper limb spasticity.
Gracies JM; O'Dell M; Vecchio M; Hedera P; Kocer S; Rudzinska-Bar M; Rubin B; Timerbaeva SL; Lusakowska A; Boyer FC; Grandoulier AS; Vilain C; Picaut P;
Muscle Nerve; 2018 Feb; 57(2):245-254. PubMed ID: 28590525
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension.
Gracies JM; Esquenazi A; Brashear A; Banach M; Kocer S; Jech R; Khatkova S; Benetin J; Vecchio M; McAllister P; Ilkowski J; Ochudlo S; Catus F; Grandoulier AS; Vilain C; Picaut P;
Neurology; 2017 Nov; 89(22):2245-2253. PubMed ID: 29093068
[TBL] [Abstract][Full Text] [Related]
6. Composite active range of motion (CX
Bayle N; Maisonobe P; Raymond R; Balcaitiene J; Gracies JM
Clin Rehabil; 2020 Jun; 34(6):803-811. PubMed ID: 32336148
[TBL] [Abstract][Full Text] [Related]
7. Systematic literature review of abobotulinumtoxinA in clinical trials for adult upper limb spasticity.
Dashtipour K; Chen JJ; Walker HW; Lee MY
Am J Phys Med Rehabil; 2015 Mar; 94(3):229-38. PubMed ID: 25299523
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat-treatment study.
Delgado MR; Tilton A; Carranza-Del Río J; Dursun N; Bonikowski M; Aydin R; Maciag-Tymecka I; Oleszek J; Dabrowski E; Grandoulier AS; Picaut P;
Dev Med Child Neurol; 2021 May; 63(5):592-600. PubMed ID: 33206382
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Hemiparesis in Adults with Lower Limb Spasticity Previously Treated With Other Botulinum Toxins: A Secondary Analysis of a Randomized Controlled Trial.
Esquenazi A; Stoquart G; Hedera P; Jacinto LJ; Dimanico U; Constant-Boyer F; Brashear A; Grandoulier AS; Vilain C; Picaut P; Gracies JM
PM R; 2020 Sep; 12(9):853-860. PubMed ID: 32108436
[TBL] [Abstract][Full Text] [Related]
10. Spasticity and Range of Motion Over Time in Stroke Patients Who Received Multiple-Dose Botulinum Toxin Therapy.
Ro T; Ota T; Saito T; Oikawa O
J Stroke Cerebrovasc Dis; 2020 Jan; 29(1):104481. PubMed ID: 31699575
[TBL] [Abstract][Full Text] [Related]
11. Early AbobotulinumtoxinA (Dysport
Rosales RL; Balcaitiene J; Berard H; Maisonobe P; Goh KJ; Kumthornthip W; Mazlan M; Latif LA; Delos Santos MMD; Chotiyarnwong C; Tanvijit P; Nuez O; Kong KH
Toxins (Basel); 2018 Jun; 10(7):. PubMed ID: 29933562
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of OnabotulinumtoxinA 400 Units in Patients with Post-Stroke Upper Limb Spasticity: Final Report of a Randomized, Double-Blind, Placebo-Controlled Trial with an Open-Label Extension Phase.
Abo M; Shigematsu T; Hara H; Matsuda Y; Nimura A; Yamashita Y; Takahashi K
Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085529
[TBL] [Abstract][Full Text] [Related]
13. OnabotulinumtoxinA for the Treatment of Poststroke Distal Lower Limb Spasticity: A Randomized Trial.
Wein T; Esquenazi A; Jost WH; Ward AB; Pan G; Dimitrova R
PM R; 2018 Jul; 10(7):693-703. PubMed ID: 29330071
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial.
Brashear A; McAfee AL; Kuhn ER; Fyffe J
Arch Phys Med Rehabil; 2004 May; 85(5):705-9. PubMed ID: 15129392
[TBL] [Abstract][Full Text] [Related]
15. Coefficients of impairment in deforming spastic paresis.
Gracies JM
Ann Phys Rehabil Med; 2015 Jun; 58(3):173-8. PubMed ID: 26027752
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke.
Bakheit AM; Thilmann AF; Ward AB; Poewe W; Wissel J; Muller J; Benecke R; Collin C; Muller F; Ward CD; Neumann C
Stroke; 2000 Oct; 31(10):2402-6. PubMed ID: 11022071
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis.
Dong Y; Wu T; Hu X; Wang T
Eur J Phys Rehabil Med; 2017 Apr; 53(2):256-267. PubMed ID: 27834471
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of letibotulinumtoxinA(BOTULAX®) in treatment of post stroke upper limb spasticity: a randomized, double blind, multi-center, phase III clinical trial.
Do KH; Chun MH; Paik NJ; Park YG; Lee SU; Kim MW; Kim DK
Clin Rehabil; 2017 Sep; 31(9):1179-1188. PubMed ID: 28118733
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke.
Childers MK; Brashear A; Jozefczyk P; Reding M; Alexander D; Good D; Walcott JM; Jenkins SW; Turkel C; Molloy PT
Arch Phys Med Rehabil; 2004 Jul; 85(7):1063-9. PubMed ID: 15241751
[TBL] [Abstract][Full Text] [Related]
20. Are we underestimating the clinical efficacy of botulinum toxin (type A)? Quantifying changes in spasticity, strength and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population.
Pandyan AD; Vuadens P; van Wijck FM; Stark S; Johnson GR; Barnes MP
Clin Rehabil; 2002 Sep; 16(6):654-60. PubMed ID: 12392341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
